Experts urge FDA to remove black box warning on low-dose vaginal estrogen
Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet
Urology in focus: Key moments from 2025
Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT
